trial

Intermittent Theta Burst Stimulation (iTBS) for the Treatment of Negative Symptoms in Schizophrenia

NCTId NCT00875498
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 22 (actual)
Sponsored by Hôpital le Vinatier
Primary completion 2015-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
22 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-11
Primary completion
2015-07
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Active iTBS

Sponsors

Hôpital le VinatierLead Sponsor

Investigators

2
Emmanuel Poulet, MD, PhDPrincipal Investigator
jerome brunelin, PhDStudy Director

Sites

1 total
Bron, France

Facts & assertions

4 sourced
Enrollment
22
Phase
NA
Primary Completion Date
2015-07
Status
COMPLETED
relationships
The graph out of here
drug
Active iTBS
drug
lead_sponsor
Hôpital le Vinatier
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Emmanuel Poulet, MD, PhD
person
jerome brunelin, PhD
person